IFAN FINANCIAL INC | Sales 2014 | - | Sales 2015 | - | Capitalization | 59.23L 49Cr |
|---|---|---|---|---|---|
| Net income 2014 | - 0 | Net income 2015 | -20L -17Cr | EV / Sales 2014 | - |
| Net Debt 2014 | 1L 1.22Cr | Net Debt 2015 | 6L 5.18Cr | EV / Sales 2015 | - |
| P/E ratio 2014 |
-5.71
x | P/E ratio 2015 |
-2.43
x | Employees | - |
| Yield 2014 * |
-
| Yield 2015 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Larry Williams
CEO | Chief Executive Officer | - | 07/22/07 |
Steve Scholl
DFI | Director of Finance/CFO | 73 | 28/14/28 |
| President | 57 | 28/14/28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| President | 57 | 28/14/28 | |
Steve Scholl
DFI | Director of Finance/CFO | 73 | 28/14/28 |
Larry Williams
CEO | Chief Executive Officer | - | 07/22/07 |
Palantir Bioceuticals, Inc., formerly IFAN Financial, Inc., is a biopharmaceutical company offering holistic solutions to mental health illnesses. The Company uses psychedelic-assisted psychotherapy (PAP), supervised use of ketamine, 3,4-Methylenedioxymethamphetamine (MDMA), psilocybin, Lysergic acid diethylamide (LSD), and ibogaine as part of elaborated psychotherapy programs.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +14.34% | 342.54Cr | |
| +94.45% | 182.87Cr | |
| +173.02% | 9.08Cr |
